Stock MRNA MODERNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Moderna, Inc.

Equities

MRNA

US60770K1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
125.7 USD +7.13% Intraday chart for Moderna, Inc. +2.90% +26.37%
May. 13 Moderna Insider Sold Shares Worth $1,825,220, According to a Recent SEC Filing MT
May. 10 Equities Mostly Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Moderna Announces Update on Investigational RSV Vaccine
AQ
Moderna Insider Sold Shares Worth $1,825,220, According to a Recent SEC Filing
MT
Equities Mostly Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey
MT
S&P 500, Dow Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey
MT
Sector Update: Health Care Stocks Higher Late Afternoon
MT
Novavax Surges on $1.2 Billion Sanofi Vaccine Deal
MT
Equity Markets Mixed Intraday After Consumer Sentiment Survey
MT
Sector Update: Health Care Stocks Advance Friday Afternoon
MT
Trending : Moderna's Proposed RSV Vaccine Faces Delayed FDA Review
DJ
Top Midday Stories: Biden to Reportedly Quadruple Chinese EV Tariffs; Novavax Shares Soar on Sanofi Deal News; Protesters Try to Break Into Tesla's Plant in Germany; FDA Pushes Back Approval of Moderna Vaccine
MT
Moderna: FDA delays review of mRNA-1345
CF
Sector Update: Health Care Stocks Edge Higher Premarket Friday
MT
Moderna's RSV Vaccine Review Delayed by FDA to End of May
MT
US FDA Delays Approval of Moderna's RSV Vaccine Biologics License Application
MT
US FDA Delays Approval of Moderna's RSV Vaccine Biologics License Application
MT
Moderna : FDA Extends RSV Vaccine Review, But No Issues Flagged
DJ
FDA Delays Approval of Moderna's RSV Vaccine
MT
Moderna Announces Update on Investigational Rsv Vaccine
CI
US FDA pushes decision on Moderna's RSV vaccine to end of this month
RE
Deutsche Bank Raises Moderna's Price Target to $85 From $70
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW